Scott Q Siler, Ph.D.

President, DILIsym Services, Inc.
Associate Director, DILI-sim

Scott Q Siler, Ph.D. is the president of DILIsym Services, Inc., a company developing and using DILIsym® software to improve the development of safer drug therapies. He has served on the Board of Directors of the company since 2016. He is also an associate director of the DILI-sim Initiative since joining in 2011. He is co-project lead on the development of the DILIsym® software and is a project manager for DILIsym® services projects contracted by pharmaceutical companies. In addition to his duties in helping manage and advance the business of DILIsym Services, Dr. Siler continues to be a scientific contributor to DILIsym® services projects and development. Dr. Siler is leading the company’s efforts in the development of NAFLDsym™ software, computational model of non-alcoholic fatty liver disease (NAFLD) that can be used to predict efficacy for treatment modalities developed for treating NAFLD.

Dr. Siler worked for more than 12 years integrating physiology and mathematics with Entelos, a provider of in silico modeling and simulation products and consulting services. Dr. Siler also managed and contributed to the development of the Metabolism PhysioLab. Additionally, while at Entelos, he led multiple projects evaluating potential treatments for type 2 diabetes.

Dr. Siler graduated with a Ph.D. in nutrition and a bachelor of arts in biochemistry and molecular biology from the University of California, Berkeley.